Day: January 26, 2017

Most discussions about data integrity revolve around misconduct by sponsors and CROs. An often silent topic is fraud by patients participating in trials. Recently there were reports of extensive fraud by subjects participating in Phase 1 clinical trials in China. Subjects would routinely manipulate biological samples, use fake IDs to get around recruitment restrictions, and … Read more

Peer-reviewed publication of clinical trial results, expert opinions and patient advocacy groups are frequently used to support market approval of drugs and public policy discussions. A series of articles published last week raise serious questions about the conflict of interest issues in such information. Major aspects of public discussions involving new drugs may be tainted … Read more